CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma

• DOI: 10.1371/journal.pone.0247020
• Publication Date: 2021-02-16T22:02:08Z
• Authors: Xiaoling Liu; Yichen Jia; Changyuan Shi; Dechen Kong; Yuanming Wu; Tiantian Zhang; Anjie Wei; Dan Wang
• Keywords: Male; 0303 health sciences; Science; Q; R; Adenocarcinoma of Lung; Middle Aged; Prognosis; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Biomarkers, Tumor; Medicine; Humans; Female; Aryl Hydrocarbon Hydroxylases; Molecular Targeted Therapy; Research Article; Aged

CYP4B1 belongs to the mammalian CYP4 enzyme family and is predominantly expressed in lungs of humans. It responsible for oxidative metabolism a wide range endogenous compounds xenobiotics. In this study, using data from The Cancer Genome Atlas (TCGA) project Gene Expression Omnibus (GEO) database, secondary analysis was performed explore expression profile , as well its prognostic value patients with lung adenocarcinoma (LUAD). Based on obtained results, significantly decreased discovered LUAD when compared their normal counterparts ( p <0.05), linked age younger than 65 years = 0.0041), history pharmaceutical 0.0127) radiation 0.0340) therapy, mutations KRAS/EGFR/ALK 0.0239), living status dead 0.0026). Survival indicated that low an independent indicator shorter survival terms overall (OS) recurrence-free (RFS) LUAD. copy number alterations (CNAs) sites cg23440155 cg23414387 hypermethylation might contribute expression. set enrichment (GSEA) suggested act oncogene by preventing biological pathways exogenous enhancing DNA replication cell cycle activities. conclusion, may serve valuable biomarker potential therapeutic target